Meeting of the WHO expert working group on surveillance of influenza antiviral susceptibility, Geneva, July 2013.
D019943:Amino Acid Substitution; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy / Q000453:epidemiology / Q000821:virology*; D020128:Inhibitory Concentration 50; D008826:Microbial Sensitivity Tests / Q000379:methods; D009439:Neuraminidase / Q000037:antagonists & inhibitors; D009975:Orthomyxoviridae / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics; D011159:Population Surveillance; D014763:Viral Matrix Proteins / Q000037:antagonists & inhibitors; D014944:World Health Organization; D000086082:Viroporin Proteins
D000998:Antiviral Agents; D009439:Neuraminidase; D014763:Viral Matrix Proteins; C488937:M2 protein, Influenza A virus; D000086082:Viroporin Proteins